In Europe and North America, >20% of the population is aged ≥65 years, and this percentage will reach 30% by the middle of this century in many developed countries 1 . Cardiovascular disease (CVD) is the foremost cause of death and disability among elderly individuals in the Western world 1 . CVD is a disease of ageing; currently, approximately 66% of CVDs occur in patients aged ≥75 years 1 . Age-specific mortality from CVD exponentially increases with age throughout the later years of life 1 . It is becoming evident that ageing results in well-defined phenotypic changes that render the coronary circulation prone to disease even in the absence of traditional risk factors (such as hypertension, metabolic diseases, and smoking). For example, ageing results in complex dysregulation of microvascular perfusion; pro-atherogenic and pro-inflammatory effects; alterations in the extracellular matrix that affect vascular stability; and changes in the secretory, transport, and barrier functions of vascular cells. An understanding of the mechanisms implicated in age-related impairment of the coronary circulation is essential for reducing cardiovascular mortality in an ageing population. In this Review, the effect of ageing on the functional and structural integrity of the coronary circulation is considered in terms of potential mechanisms involved in endothelial dysfunction and age-related impairment of angiogenesis.
In Europe and North America, >20% of the population is aged ≥65 years, and this percentage will reach 30% by the middle of this century in many developed countries 1 . Cardiovascular disease (CVD) is the foremost cause of death and disability among elderly individuals in the Western world 1 . CVD is a disease of ageing; currently, approximately 66% of CVDs occur in patients aged ≥75 years 1 . Age-specific mortality from CVD exponentially increases with age throughout the later years of life 1 . It is becoming evident that ageing results in well-defined phenotypic changes that render the coronary circulation prone to disease even in the absence of traditional risk factors (such as hypertension, metabolic diseases, and smoking). For example, ageing results in complex dysregulation of microvascular perfusion; pro-atherogenic and pro-inflammatory effects; alterations in the extracellular matrix that affect vascular stability; and changes in the secretory, transport, and barrier functions of vascular cells. An understanding of the mechanisms implicated in age-related impairment of the coronary circulation is essential for reducing cardiovascular mortality in an ageing population. In this Review, the effect of ageing on the functional and structural integrity of the coronary circulation is considered in terms of potential mechanisms involved in endothelial dysfunction and age-related impairment of angiogenesis.
The consequences of combined functional and structural impairment of the coronary circulation are discussed.
Endothelial dysfunction in ageing
A large body of evidence suggests that impaired endothelium-dependent nitric oxide (NO)-mediated vasodilatation (endothelial dysfunction) is associated with cardiovascular events, as reviewed previously 2 . Preclinical and clinical studies demonstrate that ageing is a major cause of endothelial dysfunction [3] [4] [5] . Endothelial dysfunction is an early feature of atherosclerotic vascular diseases and substantially contributes to impaired microvascular perfusion.
Endothelium-derived NO is a critical vasodilator that regulates vascular resistance and tissue perfusion. In addition to maintaining normal organ blood flow, endothelium-derived NO also exerts important vasoprotective and cardioprotective effects. For example, NO regulates cell division and survival, inhibits platelet aggregation and inflammatory cell adhesion to endothelial cells, disrupts pro-inflammatory cytokine-induced signalling pathways, preserves endothelial progenitor cell function, and regulates mitochondrial function and cellular energy metabolism 1 . Endothelial dysfunction and consequential impaired bioavailability of NO promote the pathogenesis of CVD and hypertension, Abstract | Ageing is the main risk factor for the development of cardiovascular diseases. A central mechanism by which ageing promotes vascular pathologies is compromising endothelial health.
The age-related attenuation of endothelium-dependent dilator responses (endothelial dysfunction) associated with impairment of angiogenic processes and the subsequent pathological remodelling of the microcirculation contribute to compromised tissue perfusion and exacerbate functional decline in older individuals. This Review focuses on cellular, molecular, and functional changes that occur in the endothelium during ageing. We explore the links between oxidative and nitrative stress and the conserved molecular pathways affecting endothelial dysfunction and impaired angiogenesis during ageing. We also speculate on how these pathological processes could be therapeutically targeted. An improved understanding of endothelial biology in older patients is crucial for all cardiologists because maintenance of a competently functioning endothelium is critical for adequate tissue perfusion and long-term cardiac health.
vascular cognitive impairment, and a range of pathological conditions from erectile dysfunction to claudication. The critical role of endothelium-derived NO in cardiovascular protection in ageing is emphasized by the finding that endothelial NO synthase (eNOS; also known as NOS3)-deficient mice have a premature cardiac ageing phenotype that is associated with early mortality 6 . The mechanisms underlying age-related endothelial dysfunction are multifaceted and are likely to involve increased oxidative and nitrative stress and alterations in the conserved molecular pathways affecting common ageing processes (Fig. 1) .
Oxidative stress. The free radical theory of ageing, first proposed by Harman 7 , postulates that age-related physiological decline is determined by the endogenous production of reactive oxygen species (ROS) in cells, resulting in cumulative macromolecular damage. Although the role of ROS in regulation of lifespan is still debated, important components of the theory have been substantiated. Since the early 2000s, several groups have reported that increased levels of ROS contribute substantially to vascular ageing by promoting endothelial dysfunction in both aged laboratory animals 4 and older adults 8, 9 . One of the functional consequences of increased ROS production in aged endothelial cells is inactivation of NO and subsequent vasomotor dysfunction 4, [10] [11] [12] . Impaired bioavailability of NO owing to age-related oxidative stress severely impairs flow-induced or shear-stress-induced vasodilatation in the coronary circulation 4 , which is a critical mechanism for maintaining normal myocardial perfusion. The severe generalized impairment of NO bioavailability in ageing 13 is also likely to be exacerbated by age-related dysregulation of eNOS expression 4, [14] [15] [16] [17] , decreased availability of the NO synthase cofactor tetrahydrobiopterin 18 , and/or reduced intracellular l-arginine availability 19 . Age-related oxidative stress in the coronary vasculature is, at least in part, caused by increased activity of NADPH oxidase (NOX) 4, 10 . Accordingly, treatments that attenuate NOX activity improve endothelial function in aged coronary arteries 4 . Previous studies suggest that upregulation of endothelial NOX in the aged vasculature is due to the increased presence of pro-inflammatory mediators 20 and/or the increased activity of the reninangiotensin system 21 . In addition to promoting endothelial dysfunction, NOX might also have a central role in the pathogenesis of atherosclerosis and hypertension through activation of redox signalling pathways.
Growing evidence indicates that increased mitochondrial oxidative stress substantially contributes to age-related endothelial dysfunction. With advanced age, increased mitochondria-derived production of ROS can be detected in all tissues, including those in the cardiovascular system 22 . Studies show that treatment with mitochondria-targeted antioxidants improves endothelial function in aged mice 23, 24 . Likewise, attenuation of mitochondrial oxidative stress in a genetically modified mouse model (mCAT) of overexpression of human catalase in the mitochondria also delays age-related cardiac pathology 25 and improves endothelial function (Z.U. and A.C., unpublished observations). Conversely, genetic deletion of the mitochondrial antioxidant proteins mitochondrial superoxide dismutase [Mn] (SOD2) 26 and glutathione peroxidase 1 (reF.
27
) exacerbates age-related vascular dysfunction. The mechanisms promoting mitochondrial oxidative stress in aged endothelial cells are probably multifaceted and might include dysregulation of the electron transport chain 28 , peroxynitrite-mediated nitration and inactivation of SOD2 (reF. 29 ), decline in glutathione content 30 , or increased activity of the renin-angiotensin system. Additionally, the NOX isoform NOX4 is localized to the mitochondria, and an age-related increase in expression or activity of NOX4 can contribute to mitochondrial oxidative stress 22 . Likewise, a decline in endothelial mitochondria content owing to impaired mitochondrial biogenesis 28, 31, 32 might also contribute to increased mitochondria-derived ROS production.
The redox-sensitive transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) has a critical role in preserving a youthful endothelial phenotype. In young vessels, increased levels of ROS (as induced by metabolic diseases or hypertension) activate adaptive mechanisms that involve induction of NRF2-driven antioxidant defence mechanisms 33 . NRF2 orchestrates the transcriptional response of endothelial cells to oxidative stress, upregulating numerous proteins that detoxify ROS, as well as those with other antioxidant properties. Strong evidence indicates that age-related
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• Age-related endothelial dysfunction associated with impairment of angiogenic processes and the subsequent pathological remodelling of the microcirculation contribute to compromised tissue perfusion and exacerbate functional decline in older individuals.
• the mechanisms underlying age-related endothelial dysfunction are multifaceted and are likely to involve increased oxidative and nitrative stress and alterations in the conserved molecular pathways affecting common ageing processes.
• Age-related impairment of angiogenesis probably results from reduced nitric oxide bioavailability, metabolic dysregulation, altered angiomir expression, NrF2 dysfunction, endothelial senescence and apoptosis, alterations in anti-geronic circulating factors and inducers of angiogenesis, and impaired pericyte function.
• Anti-ageing interventions that prevent or reverse age-related endothelial dysfunction and improve angiogenesis are expected to confer cardiovascular protection and delay functional decline in older individuals, extending health span.
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vascular oxidative stress is exacerbated by a homeostatic failure owing to dysregulation of the NRF2-mediated antioxidant response in both rodent models and non-human primates 34, 35 . Strong evidence suggests a potential anti-ageing role for the gasotransmitter hydrogen sulfide (H 2 S), which is produced by the evolutionarily conserved transsulfuration pathway 36 . Endogenous H 2 S exerts vasoprotective effects, promoting vasodilatation, regulating endothelial barrier function 37 , inducing NAD-dependent protein deacetylase sirtuin 1 (SIRT1) activation, upregulating NRF2, and reducing mitochondrial oxidative stress 36 . Production of H 2 S decreases during ageing and is increased by anti-ageing interventions including caloric restriction and methionine restriction 38 . A view is emerging that combines aspects of both the free radical theory of ageing and the 'inflammageing' theory of chronic inflammation promoting ageing-related pathologies. ROS, in addition to inactivating NO and causing oxidative macromolecular damage, might also have important signalling roles in the vasculature. For example, both NOX-derived and mitochondria-derived ROS might be implicated in the pathogenesis of chronic, low-grade, sterile vascular inflammation by activating nuclear factor-κB (NF-κB) and other pro-inflammatory signalling mechanisms, upregulating vascular production of cytokines and chemokines, and promoting endothelial activation and acquisition of a senescent endothelial phenotype 22, [39] [40] [41] . Age-related endothelial dysfunction can be reversed by habitual physical activity, which probably contributes to the reduced risk of CVD associated with exercise 42 . The molecular mechanisms of endothelial protection conferred by exercise are likely to be complex and include reduced oxidative stress, mitochondrial protection, and anti-inflammatory effects 1, 18, [43] [44] [45] [46] [47] .
Nitrosative and nitrative stress. Many of the adverse consequences of oxidative stress are mediated via diffusion-limited reactions of free radicals with NO. One of the most studied and accepted physiological pathways to produce reactive nitrogen species is through SMC Ageing processes
Fig. 1 | Ageing signalling pathways that contribute to oxidative stress and endothelial dysfunction. In aged endothelial cells, increased levels of reactive oxygen species (ROS) generated by NADPH oxidases (NOXs; stimulated by elevated tumour necrosis factor (TNF) levels and/or by the activated local renin-angiotensin system (RAS) in the vascular wall) and mitochondria (mtROS) decrease the bioavailability of nitric oxide (NO) by forming peroxynitrite (ONOO − ). Lack of NO leads to vasodilator dysfunction, whereas nitrative stress leads to poly [ADP-ribose] polymerase 1 (PARP1) activation, which contributes to NAD + depletion. Impaired activity of the NAD + -dependent pro-survival factor NAD-dependent protein deacetylase sirtuin 1 (SIRT1) and the nuclear factor erythroid 2-related factor 2 (NRF2)-dependent antioxidant defence pathway exacerbates vascular oxidative stress and endothelial dysfunction in ageing. The model predicts that, in addition to these cell-autonomous mechanisms, age-related deficiency of circulating insulin-like growth factor I (IGFI) and other vasoprotective factors confers pro-oxidative vascular effects in ageing. AMPK , 5′-AMP-activated protein kinase; BH 4 , tetrahydrobiopterin; eNOS, endothelial nitric oxide synthase; mTOR , mechanistic target of rapamycin; SMC, smooth muscle cell.
the diffusion-limited reaction of NO with superoxide, which leads to formation of the highly reactive oxidant peroxynitrite 48 . Numerous preclinical studies have demonstrated increased cardiovascular peroxynitrite generation or consequent protein nitration and implicated these processes in ageing-associated cardiovascular dysfunction 4, [10] [11] [12] 49, 50 . Peroxynitrite might facilitate cardiovascular dysfunction in ageing via multiple mechanisms including increases in lipid peroxidation, protein oxidation and nitration (which leads to inactivation of important proteins and enzymes involved in regulation of vascular function, such as proteins involved in mitochondrial electron transfer, Ca 2+ handling, and NO signalling), LDL oxidation (which promotes atherogenesis), and activation of stress signalling pathways and matrix metalloproteinases (which facilitates cell death and pathological remodelling) 48 . Peroxynitrite, in concert with other oxidants, induces breaks in DNA strands, activating the nuclear DNA repair enzyme poly [ADP-ribose] polymerase 1 (PARP1), which transfers ADP-ribose units from NAD + to nuclear proteins, including transcription factors and histones; this process results in depletion of the intracellular NAD + pools and slows the rate of glycolysis and mitochondrial respiration, which eventually culminates in cellular dysfunction [51] [52] [53] . Given that both SIRT1 and PARP1 are NAD + -utilizing enzymes, induction of PARP1 decreases SIRT1 activity by consuming cellular NAD + , exacerbating vascular ageing processes in experimental animals 41 . PARP1 activation, in part via inhibition of SIRT1, has been shown to modulate the transcriptional regulation of various pro-inflammatory genes 54, 55 , such as those affected by NF-κΒ activation [56] [57] [58] . The peroxynitrite-PARP1 pathway has also been implicated in multiple human pathologies, including CVDs 59 . Importantly, PARP1 is a viable pharmacological target for vasoprotection 41, 60 .
Other conserved molecular pathways. During the past 2 decades, common themes have emerged regarding the role of overlapping evolutionarily conserved processes that promote ageing. We provide a brief overview of the available evidence on the role of some of these pathways in endothelial pathophysiology in ageing.
For endothelial biology, SIRT1 (an NAD-dependent histone deacetylase with potent anti-ageing effects 61 ) is of particular importance. SIRT1 expression and activity decrease with age in the vasculature, which is likely to contribute to endothelial dysfunction 5 . Accordingly, studies show that pharmacological activation of SIRT1 significantly improves endothelial function in aged mice 62 . Furthermore, supplementation with nicotinamide mononucleotide (NMN), an NAD + intermediate, activates SIRT1 and improves endothelial function in the aged vasculature 63 . SIRT1 and other sirtuins are considered promising drug targets 61 , and future studies should evaluate the efficacy of sirtuin-activating compounds for cardiovascular protection in older individuals.
Caloric restriction is a dietary regimen recognized to delay ageing and extend lifespan in laboratory animals [64] [65] [66] [67] . Previous studies demonstrate that caloric restriction has substantial antioxidant and anti-inflammatory vascular effects, preserving endothelial function in aged rodents 30, 65 . Importantly, these endothelial protective effects of caloric restriction also seem to be mediated by activation of SIRT1-dependent pathways 30, 65 . Initial evidence from studies in obese individuals suggests that caloric restriction also confers endothelial protective effects in humans 68 . Future studies should define the circulating factors mediating the vasoprotective effects of caloric restriction and establish the translational potential of targeting caloric restriction-sensitive pathways.
Optimal regulation of cellular energy metabolism is a crucial requirement for healthy ageing. 5′-AMP-activated protein kinase (AMPK) is an evolutionarily conserved master regulator of cellular metabolism that is known to regulate ageing processes. Initial evidence suggests that pharmacological activation of AMPK has important endothelial protective effects 69 . Inhibition of mechanistic target of rapamycin (mTOR) extends lifespan in mice and inver tebrate models and reduces or delays the pathogenesis of various age-related diseases [70] [71] [72] . mTOR is a serine/threonine-protein kinase of the phosphoinositide 3-kinase (PI3K)-related family that functions as a master regulator of cellular growth and metabolism by sensing nutrient status. The cellular mechanisms by which mTOR exerts its anti-ageing effects include the regulation of proteome dynamics, ribosomal biogenesis, and autophagy through mTOR complex 1 (reF. 73 ). Of note, evidence is accumulating that rapamycin treatment has anti-ageing vascular effects and improves endothelial function in rodent models of ageing 73 and age-related diseases 70, 74 . Strong data demonstrate that rapamycin treatment has substantial cardioprotective effects by reversing age-dependent cardiac proteome remodelling, which mimics the effects of caloric restriction 72 . Further studies are needed to test whether similar effects underlie rapamycin-mediated vasoprotection.
Several lines of evidence support the concept that unrepaired DNA damage might affect the ageing phenotype of various organ systems. Interestingly, studies show that mice with genomic instability have a phenotype similar to that seen in the setting of age-related endothelial dysfunction, raising the possibility that the DNA damage response might contribute to vascular ageing 75 . During ageing, endothelial cells can acquire a senescent phenotype, probably owing to oxidative-stress-induced DNA damage and/or mitochondrial dysfunction 1 . Preliminary evidence indicates that endothelial senescence contributes to endothelial dysfunction in ageing and the pathophysiological conditions associated with accelerated vascular ageing [76] [77] [78] . Importantly, multiple possible 'senolytic' agents, which selectively eliminate senescent cells, are under investigation to improve health span in old age. There are reports that long-term senolytic treatment (intermittent treatment with dasatinib and quercetin via oral gavage) improves endothelial function in mouse models of ageing 76 . However, understanding the exact role of the DNA damage response and senescence pathways in endothelial pathophysiology requires further investigation.
Autophagy has also been implicated in the regulation of health span and lifespan. Autophagy has multifaceted roles in vascular ageing, including in the recycling of macromolecules to provide nutrients and energy, as a degradative pathway, and as a critical regulator of organellar (particularly mitochondrial) homeostasis. Old mice treated with an autophagy-enhancing agent have improved NO-mediated vasodilatation 79 , suggesting that autophagy is impaired in aged endothelial cells, which contributes to endothelial dysfunction. Future studies should further clarify the role of impaired autophagy in vascular ageing and particularly focus on elucidating its role in mitochondrial dysfunction and oxidative stress.
Epigenetics is an area of intense current research in the ageing field, and both DNA modifications (such as cytosine methylation) and chromatin status are being examined. Technological innovation now allows examination of where in the genome alterations in DNA modification or chromatin are occurring to connect epigenetic changes to altered gene expression 80, 81 . With these advances, previous hypotheses (such as that of genomic hypomethylation) are being replaced with new insights into both tissue-specific epigenetic alterations with ageing and common changes at specific locations in the genome 82, 83 . Much research remains to be conducted into determining the epigenetic modifications that occur in specific cellular populations (such as endothelial cells) with ageing and how they affect the expression of important factors (such as eNOS) that regulate endothelial function 84 . Causal studies manipulating the epigenome at specific locations need to be performed to link these new data to functional effects, although these studies can be difficult 85 . Another important area of study is to understand how post-translational modifications to histone tails, including methylation and acetylation, regulate endothelial gene expression and function in ageing.
Finally, growing evidence suggests that neuroendocrine mechanisms also have an important role in age-related endothelial alterations 86 . In particular, the age-related decline in circulating growth hormone and consequent hepatic production of insulin-like growth factor I (IGFI) seem to contribute substantially to age-related microvascular changes. IGFI deficiency promotes the development of endothelial dysfunction, microvascular rarefaction, and atherosclerosis, as reviewed previously 87 . Studies in animal models of growth hormone and IGFI deficiency suggest that the growth hormone-IGFI axis regulates endothelial redox homeostasis by attenuating mitochondrial ROS production, upregulating NRF2, and maintaining cellular antioxidant enzyme levels 86, 88, 89 . Taken together, these results point to potential benefits of interventions preventing age-related IGFI deficiency and promoting microvascular health for prevention of CVDs in elderly individuals.
Impaired angiogenesis in ageing
Age-related alterations in endothelial phenotypes also have a profound effect on the structural integrity of the circulatory system. The dynamic balance between the processes of angiogenesis and vascular regression is critical for maintenance of the microvascular network in the heart and in other organs, including the brain. Strong evidence indicates that advanced ageing is associated with a progressive deterioration of microvascular homeostasis, at least in part owing to age-related impairment of angiogenic processes 1, [90] [91] [92] [93] [94] . The mechanisms contributing to age-related impairment of angiogenesis are likely to be multifaceted (Fig. 2) . Endothelial dysfunction and impaired NO bioavailability are thought to have critical roles in angiogenic incompetence. In addition, ageing also impairs intrinsic endothelial angiogenic processes by altering important cellular signalling pathways governing proliferation, adhesion, migration, extracellular matrix turnover, apoptosis, synthesis and release of growth factors and cytokines, smooth muscle recruitment, and vessel stabilization 94 . Furthermore, ageing also alters pro-angiogenic and antiangiogenic circulating factors and results in dysregulated availability of promoters and inhibitors of angiogenesis in various tissues.
Consequences of impaired angiogenesis. Impaired angiogenesis has been proposed to contribute to age-related decline in microvascular density 95, 96 , decreased myocardial blood supply, impaired adaptation to hypoxia 95, 97, 98 , and exacerbated ischaemic tissue injury. Impaired angio genesis also compromises recovery after tissue damage, which is likely to contribute to the worsened outcomes of myocardial ischaemia and infarction, stroke, and peripheral artery disease in older patients 94 . During the pathogenesis of cardiac hypertrophy, an imbalance between growth of the cardiac muscle and impaired angiogenesis is likely to be a critical event leading to cardiac failure. Age-related impairment of angiogenic capacity also has important implications for the utility of therapeutic strategies aimed at facilitating angiogenesis (such as administration of angiogenic growth factors) in older patients with myocardial ischaemia or peripheral artery disease.
Age-related impairment of angiogenesis is likely to have a central role in microvascular rarefaction associated with ageing 95, 96 . In addition to angiogenic incompetence of endothelial cells, removal of angiogenic stimuli, pericyte dysfunction, and upregulation of angiogenesis inhibitors are likely to contribute to age-related microvascular rarefaction. Microvascular rarefaction has been linked to both impaired tissue perfusion and development of hypertension 99 . Despite these advances, the effect of vessel loss on network and vessel-level haemo dynamics remains under-investigated. As microvascular network resistance is influenced by both the number and the connectivity (that is, architecture) of vessels, the effect of impaired angiogenesis on network haemodynamics requires evaluation of the integrated effects in both the aged heart 96 and other organs, including the brain 64 .
Impaired bioavailability of NO. Perhaps the most striking finding is that ageing promotes intrinsic angiogenic incompetence in endothelial cells. For example, primary microvascular endothelial cells derived from aged rodents have an impaired angiogenic response to exogenous administration of vascular endothelial growth factor (VEGF) (Fig. 3) , suggesting that endothelial cells become resistant to inducers of angiogenesis with age 100 . Strong evidence indicates that endothelial synthesis of NO mediates pro-angiogenic effects of VEGF 101 and other growth factors. Diminished bioavailability of endothelium-derived NO impairs the dynamic balance between processes of angiogenesis and vascular regression and promotes microvascular rarefaction. For example, microvascular rarefaction develops in the myocardium upon chronic inhibition of NO synthesis 102 and in Nos3 -/-mice 103 . Because ageing is associated with endothelial dysfunction and a decrease in NO bioavailability, these factors are likely to contribute to impairment of angiogenic processes and microvascular rarefaction with old age 91 . Importantly, the impaired angiogenic capacity of aged endothelial cells compromises the clinical response to interventions aimed to stimulate capillarization in the ischaemic myocardium in older individuals in clinical trials 94 . In this regard, it is important to note that the vast majority of preclinical trials promoting therapeutic angiogenesis are conducted in young animals, which do not recapitulate age-related endothelial dysfunction and the unresponsiveness of aged endothelial cells to inducers of angiogenesis. This discrepancy might explain the failure to translate promising experimental results into clinical benefits 94 . Interventions that restore NO bioavailability have the potential to improve angiogenesis in old age, although this hypothesis needs to be tested in future preclinical and clinical studies. For now, interventions that improve endothelial function in ageing (such as exercise and treatment with resveratrol 104 ) seem to have beneficial effects on endothelial angiogenic capacity and/or microvascular capillary density.
Metabolic dysregulation. Ageing is associated with impaired cellular bioenergetics, which directly contributes to functional decline of aged organisms. Interestingly, growing evidence indicates that cellular pathways regulating bioenergetics also affect angiogenic processes, as reviewed previously 105 . Critical bioenergetic pathways that are likely to contribute to age-related impairment of angiogenic processes include the NAD + biosynthetic pathway and activation of the NAD + -dependent anti-ageing master regulator SIRT1 (reF. 105 ). Ageing decreases cellular NAD + levels, and evidence suggests that treatment with the NAD + intermediate NMN reverses age-associated endothelial dysfunction 63 and improves endothelial angiogenic processes (Z.U. and A.C., unpublished observations). Furthermore, SIRT1 ablation in endothelial cells impairs angiogenesis, mimicking the ageing phenotype 106 , whereas treatment of aged animals with pharmacological activators of SIRT1 results in increased microvascular density 104 . In myocardial microvascular endothelial cells isolated from aged rats, treatment with a pharmacological activator of the metabolic sensor AMPK, which is linked to SIRT1 activation, also improves angiogenic processes 107 .
Dysregulation of angiomiR expression. The expression of a number of microRNAs (miRNAs) was reported to change in the heart and the vasculature with ageing 108 . Strong evidence indicates that specific miRNAs (so-called angiomiRs) [109] [110] [111] and the endoribonuclease DICER (also known as DICER1; a central enzyme of the miRNA machinery that is responsible for synthesis of mature functional miRNAs) have important roles in regulating angiogenic processes [111] [112] [113] [114] . Expression of DICER is known to change with age in many tissues 115 , including microvascular endothelial cells 100 . There are studies suggesting that age-related dysregulation of DICER-dependent miRNA expression in endothelial cells contributes to impaired angiogenesis and microvascular rarefaction in aged rodents 65, 100 . Overexpression of DICER in aged rat endothelial cells improves angiogenic processes, whereas downregulation of DICER in young endothelial cells resulted in impaired angiogenesis, mimicking the ageing phenotype 100 . Experimental studies suggest that among the angiomiRs that are dysregulated in ageing 100 , increased expression of miR125a-5p is causally linked to dysregulation of eNOS and VEGF in mouse endothelial cells 116 . Further studies are warranted to understand the role of the cell-autonomous and non-cell-autonomous mechanisms contributing to age-related changes in miRNA processing and expression in endothelial cells and to link these changes to specific angiogenic pathways. NRF2 dysfunction. NRF2 has a critical role in maintaining the functional integrity of the microvasculature [33] [34] [35] 65 . Evidence suggests that NRF2 also regulates angiogenic processes in endothelial cells and that genetic depletion of NRF2 impairs angiogenic responses induced by VEGF 117, 118 . Ageing is associated with NRF2 dysfunction in endothelial cells 34, 35 , which might be a contributing factor underlying age-related impairment of angiogenesis. Of note, treatment with resveratrol, a potent inducer of NRF2 activation, improves capillarization in the brain of aged rodents 104 .
Endothelial senescence. Senescent endothelial cells do not proliferate, and their capacity to form new vascular structures is impaired 119 . Indirect evidence for a causal role of endothelial senescence in impaired angiogenesis and microvascular rarefaction is derived from studies on irradiated laboratory animals 120 . Irradiation is a potent inducer of endothelial DNA damage-induced senescence, which is mediated by activation of a cyclin-dependent kinase inhibitor 2A (CDKN2A)-dependent pathway 119 , which impairs endothelial angiogenic potential. Initial evidence suggests that in many cell types, including endothelial cells, ageing is associated with induction of CDKN2A-dependent pathways (A.C., unpublished observations) 121 . Future studies should determine whether elimination of senescent cells can restore angiogenic potential and/or increase microvascular density in preclinical models of ageing. Although a cause-effect relationship between telomere shortening, endothelial replicative senescence, and impaired angiogen esis has not been established, diminished angiogenic response in telomerase-deficient mouse models with critically shortened telomeres 122 as well as studies in endothelial cells with telomerase overexpression 123 indicate that telomere exhaustion might also contribute to impairment of endothelial angiogenic potential.
Endothelial apoptosis. Several lines of evidence suggest that endothelial cell apoptosis has an important regulatory role in the structural remodelling of the microvasculature. For example, endothelial apoptosis might contribute to microvascular rarefaction by counteracting cellular proliferation. Strong evidence indicates that the number of apoptotic endothelial cells both in large arteries and in microvessels substantially increases with advanced ageing 3, 20, 124, 125 . Previous studies suggest that age-related decline of NO bioavailability and upregulation of tumour necrosis factor and/or mitochondrial oxidative stress promote endothelial apoptosis in the aged vasculature 20, 124 . Systemic circulating factors. Age-related changes in circulating factors might also contribute to impaired angiogenesis in ageing 94 . Ageing-induced changes in pro-angiogenic endocrine factors are of particular importance. Such changes include an age-related decline in circulating levels of growth hormone 126 , IGFI (reF.
127
), and oestrogens, all of which regulate multiple aspects of angiogenic processes 94 . Studies in animal models of ageing and in animals with circulating growth hormone and IGFI deficiency suggest that these age-related changes are causally linked to impaired angiogenesis and microvascular rarefaction in diverse vascular beds 128 . Levels of circulating angiogenic factors, including VEGF 129 , also decline during ageing. However, impaired angiogenesis and remodelling of the microvasculature are more likely owing to changes in the local production of angiogenic or antiangiogenic factors and/or changes in endothelial responsiveness to angiogenic stimuli.
Important insights into the regulation of angiogenesis in ageing can be derived from studies on moderate caloric restriction. In laboratory rodents, caloric restriction was demonstrated to have marked microvascular protective effects, improving microvascular density in the brain 64 . Similarly, chronic intermittent fasting was also shown to have pro-angiogenic effects, increasing capillary density in the border area of the ischaemic myocardium in rats 67 . Caloric restriction seems to upregulate intrinsic angiogenic processes in endothelial cells 65 , and at least part of these pro-angiogenic effects of caloric restriction are mediated by circulating neuroendocrine factors. In support of this concept, previous studies have shown that circulating factors present in the serum of caloric-restricted non-human primates (Macaca mulatta) confer pro-angiogenic effects on cultured endothelial cells 66 . The effect of circulating factors on microvascular density in ageing was also demonstrated by studies using heterochronic parabiosis, which involves surgically connecting the circulatory system of a young and an aged mouse 130 . Cerebromicrovascular density typically declines with ageing 95 , and the aforementioned studies suggest that circulating factors present in young animals can rejuvenate microvascular architecture in aged heterochronic parabionts 130 . The potential anti-ageing factors that improve capillarization include growth/ differentiation factor 11 (reF. 130 ). Further studies are needed to determine how capillary density in the heart is affected by blood factors that change with ageing.
Dysregulation of promoters and inhibitors of angiogenesis. Ageing alters the angiogenesis gene expression signature in the heart (Fig. 3) and other tissues 131 , fostering an antiangiogenic microenvironment. Age-related changes affect expression of both promoters and inhibitors of angiogenesis (such as thrombospondins 132 ), and the net effect is likely to promote an antiangiogenic phenotype. Ageing is associated with downregulation of VEGF, a major regulator of angiogenesis in many tissues [133] [134] [135] , and/or resistance to the effects of VEGF 136 . The expression of several other pro-angiogenic factors is also impaired in ageing, including expression of IGFI and platelet-derived growth factor (PDGF) 137 . Pituitary adenylate cyclase-activating polypeptide (PACAP) is an evolutionarily conserved neuropeptide secreted by endothelial cells that confers important anti-ageing effects. Interestingly, studies show that in aged endothelial cells, disruption of autocrine PACAP signalling might contribute to impaired angiogenic capacity 138 .
Impaired endothelial progenitor cell function.
Endothelial progenitor cells (EPCs), which can give rise to both endothelial and mural cell types 139 , are implicated in angiogenesis stimulated by conditions such as coronary artery disease. Although the definition of true endothelial progenitors is still controversial, and data on whether the total EPC number is altered by ageing are controversial [140] [141] [142] , studies suggest that the function of circulating EPCs is altered in old age 141, 143, 144 . The ageing-induced impairment of EPC function is likely to be mediated, at least in part, by an imbalance between factors promoting cell proliferation, migration, and survival and mediators promoting oxidative stress and inducing apoptosis and/or senescence [144] [145] [146] . Preliminary evidence suggests that aspects of age-related EPC dysfunction are reversible by anti-ageing interventions 147 and/or by regular aerobic exercise 148 . Preclinical studies also provide evidence that the serum factors derived from young rats have beneficial effects on EPCs isolated from aged rats 149 .
Impaired pericyte function.
Pericytes have an important role in angiogenesis and maintenance of the structural integrity of the microcirculatory network [150] [151] [152] . Pericytes are recruited to endothelial cells via PDGF-PDGF receptor-β signalling, and given their regulation of growth factor presentation, capillary diameter, permeability, endothelial cell proliferation, and local extracellular matrix density, pericytes are a novel therapeutic target [150] [151] [152] . Although age-related changes in pericytes in the heart remain under-investigated, evidence indicates that in other organs, including the brain 150, 153 and the kidneys 154 , an age-related loss of pericyte coverage of microvessels contributes to functional and structural impairment of the microcirculatory network. However, some of the age-related changes in pericyte phenotype seem to be tissue-specific or network-region-specific 155 . The apparent knowledge gap, lack of characterization in the heart, and the focus on unstimulated tissue scenarios highlight the opportunity and need for the comprehensive characterization of pericyte phenotype, morphology, and function over the time course of angiogenesis in aged microvascular networks across multiple tissue types.
Conclusions
Although substantial progress has been achieved in characterizing ageing-induced alterations in endothelial function and endothelial angiogenic phenotypes, the specific roles for cell-autonomous (such as mitochondrial dysfunction) and non-cell-autonomous (such as effects mediated by circulating factors) mechanisms need to be elucidated further. Reasonable consensus exists that NOX-derived and mitochondria-derived ROS have critical roles in vascular ageing by promoting endothelial dysfunction. Further investigation is warranted to develop treatments with translational potential, which can improve coronary perfusion in older adults by interfering with these pathways and thereby prevent or delay the pathogenesis of CVD. The concept that evolutionarily conserved molecular pathways control ageing processes in mammals raises the question of whether pharmacological or nutritional modulation of these pathways might be effective in improving endothelial function and/or restoring endothelial angiogenic capacity. In the context of angiogenesis, treatment strategies focusing on the delivery of angiogenic agents could be complemented by anti-ageing interventions that improve endothelial health. Promising examples include sirtuin activator compounds 61 and treatments that restore cellular energetics and NAD + levels (such as PARP1 inhibitors). Therefore, research efforts should persist in these directions to elucidate fully the roles of fundamental ageing processes in vascular pathophysiology and their interaction with other risk factors that contribute to the increased cardiovascular morbidity and mortality in older adults.
